Application No. 10/570,125

Paper Dated: August 24, 2009

In Reply to USPTO Correspondence of February 24, 2009

Attorney Docket No. 4647-060533

## **AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application.

## **Listing of Claims**

Claim 1. (Currently Amended) A method for manipulating the-an intrinsic strain of a celleells, comprising culturing the cell on a substrate or in a medium, thereby forming a cultured cell; and administering to treating the cultured cells either in vivo or in vitro with compounds a compound that affect the resets the intrinsic strain setpoint of the celleells in order to modulate extracellular matrix synthesis, secretion, stiffness, organization and/or remodeling, or attachment of the cells to the matrix via intergins or other like cell-matrix attachments. wherein the compound is a cytokine that adjusts the intrinsic strain of the cell by modulating a cytoskeletal gene.

Claim 2. (Currently Amended) The method according to claim 1, wherein the cells cell comprises comprise an in situ native tissue.

Claim 3. (Currently Amended) The method according to claim 1, wherein the cell comprises cells comprise an in vitro fabricated tissue engineered construct.

Claim 4. (Currently Amended) The method according to claim 3, wherein the tissue engineered construct is a human tendon internal fibroblast (HTIF)-populated bioartificial tendon (BATTM) or other fibroblast from another connective tissue.

Claim 5. (Currently Amended) The method according to claim 3, wherein the compound is added at the beginning, during or after at the end of fabrication of the tissue engineered construct is fabricated.

Claim 6. (Currently Amended) The method according to claim 1, further comprising applying a mechanical external strain to the cellscell.

RW7366.DOC

Application No. 10/570,125

Paper Dated: August 24, 2009

In Reply to USPTO Correspondence of February 24, 2009

Attorney Docket No. 4647-060533

Claim 7. (Currently Amended) The method according to claim 6, wherein the mechanical external strain is comprised of uniaxially loading a tissue engineered construct by placing Arctangle<sup>TM</sup>—loading posts beneath a well of a culture plate and applying a vacuum to deform a flexible membrane downward so as to apply a uniaxial strain along a long axis of the tissue engineered construct.

Claims 8 - 12 (Cancelled).

Claim 13. (Currently Amended) The method according to claim 1, wherein the compound is a cytokine which adjusts the intrinsic strain of cells by modulating gene expression, said gene expression selected from the group consisting of cytoskeletal genes that express cytoskeletal proteins protein is selected from the group consisting of actin, myosin, α-actinin, vinculin, and titin and others; genes; genes that express elastin; and genes that express matric metalloproteinases.

Claim 14. (Currently Amended) The method according to claim 13, wherein the cytokine is selected from the group consisting of interleukin-1 beta (IL-1 $\beta$ ) and tumor necrosis factor-alpha (TNF- $\alpha$ )-(TGF- $\alpha$ ).

Claims 15-18 (Cancelled)

Claim 19. (New) The method according to claim 1, wherein the cytoskeletal gene is a gene that expresses or regulates the expression of elastin or matrix metalloproteinase.

Claim 20. (New) The method according to claim 1, wherein the cytokine is interleukin-1 beta (IL-1β).